文献速递免疫规划传染病防控与疫情报告

2021年塔吉克斯坦2型新型口服脊灰疫苗免疫活动后血清学反应评估:一项基于人群的研究

Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021.
PubMed 文献 · Lancet Glob Health · 2022-01-01

2021年塔吉克斯坦使用2型新型口服脊灰疫苗(nOPV2)控制2型循环疫苗衍生脊灰病毒(cVDPV2)疫情。该社区血清学调查纳入2016年1月1日后出生的儿童,评估接种一剂和两剂nOPV2后2型脊灰抗体血清阳性率与血清转换。结果显示接种一剂后血清阳性率从26%升至77%,两剂后为83%;作者认为nOPV2可适用于cVDPV2疫情应对。

要点

  • 接种一剂nOPV2后2型抗体血清阳性率从26%升至77%,升幅51个百分点,有统计学意义。
  • 接种第二剂后血清阳性率83%,较第一剂后升6个百分点,无统计学意义(p=0.12)。
  • 第一剂血清转换率67%显著高于第二剂44%(χ2 p=0.010);两剂总血清转换率77%。

核心结论

  • 研究表明塔吉克斯坦nOPV2疫情应对免疫活动后产生了较强的免疫反应,结果支持既往临床试验关于nOPV2可产生2型脊灰病毒免疫力的数据,并提供证据表明nOPV2可适用于cVDPV2疫情应对。
  • 作者认为应加速nOPV2的许可和世界卫生组织预认证,以促进该疫苗更广泛使用。

研究设计与样本

  • 这项社区血清学调查纳入塔吉克斯坦七个区2016年1月1日后出生的儿童,在nOPV2免疫活动前及第一轮和第二轮后采集干血斑卡,送至美国疾病控制与预防中心(亚特兰大)做微量中和试验检测脊灰抗体。
  • 主要终点为评估接种一剂和两剂nOPV2后2型脊灰病毒血清阳性率变化和血清转换。
  • 236名入组儿童中228名(97%)纳入分析。

主要发现

  • 2型抗体血清阳性率在nOPV2接种前为26%(53/204;95%CI 20至33),接种一剂后为77%(161/210;70至82),接种两剂后为83%(174/209;77至88)。
  • 基线至接种一剂后血清阳性率升高51个百分点(42至59),p<0.0001,有统计学意义;第一剂至第二剂间升高6个百分点(-2至15),p=0.12,无统计学意义。
  • 第一剂nOPV2血清转换率为67%(89/132;59至75),显著高于第二剂的44%(20/45;30至60;χ2 p=0.010)。
  • 两剂nOPV2后总血清转换率为77%(101/132;68至83)。

临床怎么用

  • 作者认为nOPV2可适用于cVDPV2疫情应对,并建议加速其许可和世界卫生组织预认证以促进更广泛使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel oral poliovirus vaccine type 2 (nOPV2) was used to control an outbreak of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We measured seroconversion and seroprevalence of type 2 polio antibodies in children who were reported to have received two doses of nOPV2 in outbreak response campaigns. METHODS: In this community serosurvey, children born after Jan 1, 2016 were enrolled from seven districts in Tajikistan. Dried blood spot cards were collected before nOPV2 campaigns and after the first and second rounds of the campaigns and were sent to the Centers for Disease Control and Prevention (Atlanta, GA, USA) for microneutralisation assay to determine presence of polio antibodies. The primary endpoint was to assess change in seroprevalence and seroconversion against poliovirus serotype 2 after one and two doses of nOPV2. FINDINGS: 228 (97%) of 236 enrolled children were included in the analysis. The type 2 antibody seroprevalence was 26% (53/204; 95% CI 20 to 33) before nOPV2, 77% (161/210; 70 to 82) after one dose of nOPV2, and 83% (174/209; 77 to 88) after two doses of nOPV2. The increase in seroprevalence was statistically significant between baseline and after one nOPV2 dose (51 percentage points [42 to 59], p<0·0001), but not between the first and second doses (6 percentage points [-2 to 15], p=0·12). Seroconversion from the first nOPV2 dose, 67% (89/132; 59 to 75), was significantly greater than that from the second nOPV2 dose, 44% (20/45; 30 to 60; χ2 p=0·010). Total seroconversion after two nOPV2 doses was 77% (101/132; 68 to 83). INTERPRETATION: Our study demonstrated strong immune responses following nOPV2 outbreak response campaigns in Tajikistan. Our results support previous clinical trial data on the generation of poliovirus type 2 immunity by nOPV2 and provide evidence that nOPV2 can be appropriate for the cVDPV2 outbreak response. The licensure and WHO prequalification of nOPV2 should be accelerated to facilitate wider use of the vaccine. FUNDING: World Health Organization, Centers for Disease Control and Prevention, and Rotary International.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Mirzoev A, Macklin GR, Zhang Y, et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Lancet Glob Health. 2022. PMID: 36400086. doi:10.1016/S2214-109X(22)00412-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。